Last 3.85 GBp
Change Today +0.125 / 3.36%
Volume 1.5M
OXB On Other Exchanges
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

oxford biomedica plc (OXB) Snapshot

3.73 GBp
Previous Close
3.73 GBp
Day High
3.85 GBp
Day Low
3.73 GBp
52 Week High
09/15/14 - 3.95 GBp
52 Week Low
04/29/14 - 1.83 GBp
Market Cap
Average Volume 10 Days
-0.0072 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for OXFORD BIOMEDICA PLC (OXB)

Related News

No related news articles were found.

oxford biomedica plc (OXB) Related Businessweek News

No Related Businessweek News Found

oxford biomedica plc (OXB) Details

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

106 Employees
Last Reported Date: 05/4/14
Founded in 1995

oxford biomedica plc (OXB) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 429.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 260.0K GBP
Senior Vice President of Commercial Developme...
Total Annual Compensation: 225.0K GBP
Compensation as of Fiscal Year 2013.

oxford biomedica plc (OXB) Key Developments

Oxford BioMedica PLC Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Oxford BioMedica PLC announced unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported revenue was £4.73 million against £2.11 million a year ago. Operating loss was £5.42 million against £6.74 million a year ago. Loss before tax was £5.62 million against £6.7 million a year ago. Loss was £4.8 million against £5.86 million a year ago. Basic and diluted loss per ordinary share was 0.32 pence against 0.41 pence a year ago. This is primarily due to the gross margin earned from the Novartis revenues in the first half of 2014, off set by the absence of the Sanofi deferred revenue from the 2009 $26 million upfront payment. Net cash used in operating activities was £4.97 million against £6.7 million a year ago. Purchase of property, plant and equipment was £0.050 million against £0.546 million a year ago.

Oxford Biomedica PLC Appoints Dr. Paul Blake as Chief Development Officer, Effect from 1 September 2014

Oxford BioMedica PLC announced that Dr. Paul Blake, a Non-Executive Director of the Company, has been appointed to the Executive Management team as Chief Development Officer of Oxford BioMedica with effect from 1 September 2014. Paul will remain a member of the Board and will assume responsibility for the clinical development of Oxford BioMedica's pipeline of gene and cell therapies. Paul joined the Board of Oxford BioMedica in January 2010. He is a senior pharmaceutical executive with more than 30 years' experience gained from roles in international pharmaceutical and biotech companies and he has been involved in the development of many drugs and vaccines including Requip, Coreg and Provigil®. Most recently, Paul was Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, from 2006 to 2014.

Oxford BioMedica PLC to Report First Half, 2014 Results on Aug 28, 2014

Oxford BioMedica PLC announced that they will report first half, 2014 results on Aug 28, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXB:LN 3.85 GBp +0.125

OXB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €8.40 EUR +0.122
BTG PLC 662.00 GBp +4.50
Pharming Group NV €0.38 EUR -0.006
Swedish Orphan Biovitrum AB kr77.80 SEK +0.40
Veloxis Pharmaceuticals A/S kr1.91 DKK +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation OXB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.9x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD BIOMEDICA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at